Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1987 2
1988 2
1989 1
1990 2
1991 2
1993 2
1994 2
1995 3
1996 1
1997 2
1998 2
1999 4
2000 2
2001 4
2002 4
2004 3
2005 8
2006 7
2007 5
2008 3
2009 5
2010 7
2011 6
2012 8
2013 5
2014 12
2015 18
2016 13
2017 17
2018 17
2019 10
2020 12
2021 14
2022 13
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Myelofibrosis.
Passamonti F, Mora B. Passamonti F, et al. Blood. 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. Blood. 2023. PMID: 36416738 Free PMC article. Review.
Currently available clinical-based and integrated clinical/molecular-based scoring systems predict the survival of patients with MF and are applied for conventional treatment decision-making, indication to stem cell transplant (SCT) and allocation in clinical …
Currently available clinical-based and integrated clinical/molecular-based scoring systems predict the survival of pati …
Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG, Zhang L, Bennett JM, Komrokji R. Jain AG, et al. Ann Lab Med. 2022 May 1;42(3):299-305. doi: 10.3343/alm.2022.42.3.299. Ann Lab Med. 2022. PMID: 34907099 Free PMC article. Review.
Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international prognostic scoring system (IPSS-R). Bone marrow fibrosis (BMF) has been identified as an independent risk fact …
Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international progn …
Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Shahin OA, et al. Acta Haematol. 2021;144(5):484-499. doi: 10.1159/000512929. Epub 2021 Apr 21. Acta Haematol. 2021. PMID: 33882481 Free PMC article. Review.
Higher incidence of leukemic transformation has been associated with the most aggressive MPN subtype, myelofibrosis (MF); other risk factors for leukemic transformation include rising blast counts above 3-5%, advanced age, severe anemia, thrombocytopenia, leukocytosis, increasing …
Higher incidence of leukemic transformation has been associated with the most aggressive MPN subtype, myelofibrosis (MF); other risk factors …
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. Guglielmelli P, et al. J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9. J Clin Oncol. 2018. PMID: 29226763 Free article.
A Cox multivariable model was used to select from among a list of 22 variables those that were predictive of overall survival (OS). Integrated clinical and genetic prognostic models with (MIPSS70-plus) or without (MIPSS70) cytogenetic information were developed. Results Mu …
A Cox multivariable model was used to select from among a list of 22 variables those that were predictive of overall survival (OS). I …
Treating early-stage myelofibrosis.
Palandri F, Sabattini E, Maffioli M. Palandri F, et al. Ann Hematol. 2019 Feb;98(2):241-253. doi: 10.1007/s00277-018-3526-z. Epub 2018 Oct 20. Ann Hematol. 2019. PMID: 30343328 Review.
Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm associated with bone marrow fibrosis, splenomegaly, a high symptom burden, and poor prognosis. ...With the advent of targeted therapies, such as the Janus kinase inhibitors, …
Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm associated with bone marrow fibrosis …
Thrombopoietin-receptor agonists.
Basciano PA, Bussel JB. Basciano PA, et al. Curr Opin Hematol. 2012 Sep;19(5):392-8. doi: 10.1097/MOH.0b013e328356e909. Curr Opin Hematol. 2012. PMID: 22872157 Review.
The use of TPO-RAs in myelodysplastic syndrome (MDS) is questionable after reports of increasing blasts and leukemic transformation, whereas in other chemotherapy-induced thrombocytopenias (C-ITs) reports are few. Bone marrow fibrosis remains an area of activ …
The use of TPO-RAs in myelodysplastic syndrome (MDS) is questionable after reports of increasing blasts and leukemic transformation, whereas …
Idiopathic myelofibrosis.
Barosi G, Hoffman R. Barosi G, et al. Semin Hematol. 2005 Oct;42(4):248-58. doi: 10.1053/j.seminhematol.2005.05.018. Semin Hematol. 2005. PMID: 16210038 Review.
Idiopathic myelofibrosis (IMF) is characterized by anemia, progressive splenomegaly, bone marrow fibrosis, and extramedullary hematopoiesis. However, patients with a transitional myeloproliferative disorder (MPD), a prefibrotic form of myelofibrosis, or myelo …
Idiopathic myelofibrosis (IMF) is characterized by anemia, progressive splenomegaly, bone marrow fibrosis, and extramed …
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Harrison CN, et al. J Clin Oncol. 2022 May 20;40(15):1671-1680. doi: 10.1200/JCO.21.02188. Epub 2022 Feb 18. J Clin Oncol. 2022. PMID: 35180010 Free PMC article. Clinical Trial.
Secondary end points included 50% reduction in total symptom score (TSS(50)) from baseline at week 24, hemoglobin improvement, change in bone marrow fibrosis (BMF) grade, and safety. ...
Secondary end points included 50% reduction in total symptom score (TSS(50)) from baseline at week 24, hemoglobin improvement, change …
Focus on Osteosclerotic Progression in Primary Myelofibrosis.
Spampinato M, Giallongo C, Romano A, Longhitano L, La Spina E, Avola R, Scandura G, Dulcamare I, Bramanti V, Di Rosa M, Vicario N, Parenti R, Li Volti G, Tibullo D, Palumbo GA. Spampinato M, et al. Biomolecules. 2021 Jan 19;11(1):122. doi: 10.3390/biom11010122. Biomolecules. 2021. PMID: 33477816 Free PMC article. Review.
As such, neoangiogenesis, megakaryocytes hyperplasia and extensive bone marrow fibrosis, followed by osteosclerosis and bone damage, are the most relevant consequences of PMF. Moreover, bone tissue deposition, together with progressive fibrosis, represents cr …
As such, neoangiogenesis, megakaryocytes hyperplasia and extensive bone marrow fibrosis, followed by osteosclerosis and …
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J, Migliaccio AR, Kosiorek H, Bhave R, Palmer J, Kuykendall A, Mesa R, Rampal RK, Gerds AT, Yacoub A, Pettit K, Talpaz M, Komrokji R, Kremyanskaya M, Gonzalez A, Fabris F, Johnson K, Dougherty M, McGovern E, Arango Ossa J, Domenico D, Farnoud N, Weinberg RS, Kong A, Najfeld V, Vannucchi AM, Arciprete F, Zingariello M, Falchi M, Salama ME, Mead-Harvey C, Dueck A, Varricchio L, Hoffman R. Mascarenhas J, et al. Clin Cancer Res. 2023 Sep 15;29(18):3622-3632. doi: 10.1158/1078-0432.CCR-23-0276. Clin Cancer Res. 2023. PMID: 37439808 Free PMC article. Clinical Trial.
PURPOSE: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors afford symptom and spleen burden reduction but do not alter the disease course and freq …
PURPOSE: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by systemic symptoms, cytopenias, organomegaly, and bon …
196 results